Literature DB >> 28954019

Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype.

Elizabeth Maria Aparecida Barasnevicius Quagliato1, Daniel Martins Rocha1, Paula Yuri Sacai1, Sung Song Watanabe1, Solange Rios Salomão1, Adriana Berezovsky1.   

Abstract

PURPOSE: : To analyze the clinical features, visual acuity, and full-field electroretinogram (ERG) findings of 15 patients with the neuronal ceroid lipofuscinosis (NCL) phenotype and to establish the role of ERG testing in NCL diagnosis.
METHODS: : The medical records of five patients with infantile NCL, five with Jansky-Bielschowsky disease, and five with juvenile NCL who underwent full-field ERG testing were retrospectively analyzed.
RESULTS: : Progressive vision loss was the initial symptom in 66.7% of patients and was isolated or associated with ataxia, epilepsy, and neurodevelopmental involution. Epilepsy was present in 93.3% of patients, of whom 86.6% presented with neurodevelopmental involution. Fundus findings ranged from normal to pigmentary/atrophic abnormalities. Cone-rod, rod-cone, and both types of dysfunction were observed in six, one, and eight patients, respectively.
CONCLUSION: : In our study, all patients with the NCL phenotype had abnormal ERG findings, and the majority exhibited both cone-rod and rod-cone dysfunction. We conclude that ERG is a valuable tool for the characterization of visual dysfunction in patients with the NCL phenotype and is useful for diagnosis.

Entities:  

Mesh:

Year:  2017        PMID: 28954019     DOI: 10.5935/0004-2749.20170053

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  7 in total

Review 1.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

2.  Neuronal ceroid lipofuscinosis type 2: an Australian case series.

Authors:  Alexandra M Johnson; Simone Mandelstam; Ian Andrews; Katja Boysen; Joy Yaplito-Lee; Michael Fietz; Lakshmi Nagarajan; Victoria Rodriguez-Casero; Monique M Ryan; Nicholas Smith; Ingrid E Scheffer; Carolyn Ellaway
Journal:  J Paediatr Child Health       Date:  2020-04-24       Impact factor: 1.954

3.  Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.

Authors:  Sara E Mole; Angela Schulz; Eben Badoe; Samuel F Berkovic; Emily C de Los Reyes; Simon Dulz; Paul Gissen; Norberto Guelbert; Charles M Lourenco; Heather L Mason; Jonathan W Mink; Noreen Murphy; Miriam Nickel; Joffre E Olaya; Maurizio Scarpa; Ingrid E Scheffer; Alessandro Simonati; Nicola Specchio; Ina Von Löbbecke; Raymond Y Wang; Ruth E Williams
Journal:  Orphanet J Rare Dis       Date:  2021-04-21       Impact factor: 4.123

4.  Retinal degeneration in mice and humans with neuronal ceroid lipofuscinosis type 8.

Authors:  Elyse M Salpeter; Brian C Leonard; Antonio J Lopez; Christopher J Murphy; Sara Thomasy; Denise M Imai; Kristin Grimsrud; K C Kent Lloyd; Jiong Yan; Rossana Sanchez Russo; Suma P Shankar; Ala Moshiri
Journal:  Ann Transl Med       Date:  2021-08

Review 5.  Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses.

Authors:  Marina Trivisano; Alessandro Ferretti; Costanza Calabrese; Nicola Pietrafusa; Ludovica Piscitello; Giusy Carfi' Pavia; Federico Vigevano; Nicola Specchio
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

Review 6.  Neuronal ceroid lipofuscinosis in the South American-Caribbean region: An epidemiological overview.

Authors:  Guillermo Guelbert; Ana Clara Venier; Ines Adriana Cismondi; Adriana Becerra; Juan Carlos Vazquez; Elmer Andrés Fernández; Ana Lucía De Paul; Norberto Guelbert; Ines Noher; Favio Pesaola
Journal:  Front Neurol       Date:  2022-08-12       Impact factor: 4.086

7.  An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy.

Authors:  Dorothy A Thompson; Siân E Handley; Robert H Henderson; Oliver R Marmoy; Paul Gissen
Journal:  Eye (Lond)       Date:  2021-07-16       Impact factor: 3.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.